NBIX Form 4 reports multiple insider transactions
Cooke Julie reported multiple insider transaction types in a Form 4 filing for NBIX.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Cooke Julie reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 58,116 shares at a weighted average price of $124.02 per share. Following the reported transactions, holdings were 2,802 shares.
Insider Trade Summary
4,298 shares exercised/converted
Exercise
13 txns
Insider
Cooke Julie
Role
Chief Human Resources Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,401 | $0.00 | $0.00 |
| Exercise | Restricted Stock Unit | 1,510 | $0.00 | $0.00 |
| Grant/Award | Stock Option | 27,100 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Unit | 4,754 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,401 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 756 | $124.12 | $94K |
| Exercise | Common Stock | 1,510 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 815 | $124.12 | $101K |
| Grant/Award | Common Stock | 9,968 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 5,378 | $124.12 | $668K |
| Exercise | Restricted Stock Unit | 1,387 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,387 | $0.00 | $0.00 |
| Exercise Price or Tax Liability | Common Stock | 749 | $123.10 | $92K |
Holdings After Transaction:
Restricted Stock Unit — 13,227 contracts (Direct);
Stock Option — 27,100 contracts (Direct);
Common Stock — 34,170 shares (Direct)
Footnotes (9)
- F1. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold.
- F2. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award.
- F3. 32,306 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
- F4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
- F5. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,387 shares on February 12, 2026, and will vest as to 1,387 shares on February 12, 2027, 1,387 shares on February 12, 2028, and 1,387 shares on February 12, 2029, subject to the terms and conditions of the award.
- F6. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award.
- F7. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,509 shares on February 13, 2024, vested as to 1,509 shares on February 13, 2025, vested as to 1,510 shares on February 13, 2026, and will vest as to 1,510 shares on February 13, 2027, subject to the terms and conditions of the award.
- F8. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter.
- F9. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did NBIX executive Julie Cooke report on this Form 4?
Julie Cooke reported RSU vesting, related tax-withholding share dispositions, and new equity grants. She also received a large performance-based share payout and a new stock option award, all as part of her equity compensation, with no open-market stock sales disclosed.
What new stock options were granted to Julie Cooke of NBIX?
Julie Cooke received a grant of stock options covering 27,100 shares at an exercise price of $124.12 per share. One forty-eighth of these options vest and become exercisable on March 13, 2026, with additional monthly vesting of one forty-eighth thereafter.
How many Neurocrine Biosciences RSUs were newly granted to Julie Cooke?
She was granted 4,754 restricted stock units. These RSUs will vest in four equal annual installments, with one quarter of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030, subject to award conditions.
How will Julie Cooke’s new NBIX RSUs and options vest over time?
The 27,100 stock options start vesting March 13, 2026, with one forty-eighth vesting monthly. The 4,754 RSUs vest in four equal annual installments on February 13, 2027, 2028, 2029, and 2030, contingent on continued service and award terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates